A pharmacist shows a field of Mounjaro, a tirzepatide injection drug used for treating sort 2 diabetes and made by Lilly at Rock Canyon Pharmacy in Provo, Utah, Might 29, 2023.
George Frey | Reuters
The blockbuster diabetes drug Mounjaro is simpler for weight reduction than one other extremely in style remedy, Ozempic, in chubby or overweight adults, based on a large analysis of real-world information revealed Monday.
Sufferers taking Eli Lilly‘s Mounjaro have been considerably extra more likely to drop a few pounds and noticed bigger reductions in physique weight at particular time factors in comparison with these on Novo Nordisk‘s Ozempic within the study by Truveta Research. The agency compiles and analyzes affected person information from a collective of health-care programs.
The outcomes come as each medication and related remedies authorised for weight reduction soar in demand within the U.S. for his or her means to assist sufferers shed undesirable kilos over time. The broader adoption has boosted shares of Eli Lilly and Novo Nordisk this yr.
Mounjaro and Ozempic are solely authorised for the remedy of Kind 2 diabetes, however many individuals use the weekly injections off-label to drop a few pounds.
Earlier head-to-head studies have equally urged that Mounjaro is simpler than Ozempic for weight reduction and controlling blood sugar in adults with Kind 2 diabetes.
However Monday’s examine confirms Mounjaro’s edge over Ozempic in a real-world setting, particularly amongst adults who’re chubby or overweight. Notably, head-to-head scientific trials in that inhabitants usually are not but accessible, based on Truveta Analysis.
Eli Lilly is pitting Mounjaro in opposition to Wegovy, a better dose model of Ozempic authorised for weight reduction, in an ongoing clinical trial in overweight or chubby sufferers. However outcomes will not be launched till subsequent yr.
“We have been capable of evaluate the head-to-head efficacy of those two essential medicines for weight reduction upfront of randomized scientific trials,” stated Dr. Nick Stucky, an creator of the examine and vice chairman of Truveta Analysis, in a press release. “This examine may help to tell affected person care and outcomes at present, not months from now.”
Truveta Analysis particularly examined health-care information on roughly 18,000 adults who’re chubby or overweight and first began taking Mounjaro or Ozempic between Might 2022 and September 2023. Almost 52% of these sufferers had Kind 2 diabetes.
Researchers discovered that sufferers taking Mounjaro have been thrice extra more likely to lose 15% of their weight than these on Ozempic. Sufferers on Mounjaro have been additionally 2.6 instances extra more likely to obtain 10% weight reduction and 1.8 instances extra more likely to lose 5% of their weight.
These taking Mounjaro additionally skilled “considerably bigger reductions” in physique weight at particular time factors, based on Truveta Analysis.
At three months, sufferers on Mounjaro misplaced 5.9% of their weight, whereas these on Ozempic misplaced 3.6%. At six months, folks taking Mounjaro misplaced 10.1% of their weight, whereas sufferers on Ozempic misplaced 5.9%. And at one yr, these on Mounjaro misplaced 15.2% of their weight, whereas these on Ozempic misplaced 7.9%.
Truveta Analysis additionally discovered that sufferers with out Kind 2 diabetes misplaced extra weight than these with the situation. However the variations in effectiveness between Mounjaro and Ozempic have been related in each populations.
Charges of antagonistic gastrointestinal occasions have been related between sufferers taking Mounjaro and Ozempic.
Mounjaro and Ozempic are each weekly injections that change the way in which sufferers eat and result in decreased urge for food by mimicking sure hormones within the intestine. They each have weight reduction drug counterparts that use the identical energetic ingredient: Eli Lilly’s newly authorised Zepbound and Novo Nordisk’s Wegovy.
Ozempic and Wegovy solely mimic one hunger-regulating hormone known as glucagon-like peptide-1, also called GLP-1, which will increase the sensation of fullness and lowers blood sugar ranges.
In the meantime, Mounjaro and Zepbound mimic GLP-1 and one other hormone within the intestine known as glucose-dependent insulinotropic polypeptide, or GIP.
The twin strategy implies that Mounjaro and Zepbound have an enhanced impact on regulating urge for food and blood sugar ranges, which some experts say might probably result in extra important weight reduction than medicines solely concentrating on GLP-1.
In a late-stage examine of greater than 2,500 adults with weight problems however not diabetes, these taking 5 milligrams of Zepbound for 72 weeks misplaced about 16% of their physique weight on common. Greater doses of the drug have been related to much more weight reduction, with a 15-milligram dose resulting in 22.5% weight reduction on common.
Greater than two in 5 adults have weight problems, based on the Nationwide Institutes of Well being.
About one in 11 adults have extreme weight problems.